Bone formation in axial spondyloarthritis

Best Practice and Research: Clinical Rheumatology

Volumn 28, Issue 5, 2014, Pages 765-777

  Lories, Rik J ^a,b   Haroon, Nigil ^c,d  

^a SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ankylosing spondylitis; Anti TNF; Bone; Cartilage; Inflammation; Spondyloarthritis

Indexed keywords

ANOCTAMIN 6; AUTOANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EGF LIKE REPEATS AND DISCOIDIN I LIKE DOMAINS 3; HLA B27 ANTIGEN; INTEGRIN RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 23; MEMBRANE PROTEIN; NOGGIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR 4; SCLEROSTIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; BONE REMODELING; CELL POPULATION; DISEASE CLASSIFICATION; DISEASE COURSE; GENETIC ASSOCIATION; HEREDITY; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SACROILIAC JOINT; SPONDYLARTHRITIS; T LYMPHOCYTE; ANIMAL; BONE DEVELOPMENT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE PROGRESSION; HUMANS; OSTEOGENESIS; SPONDYLITIS, ANKYLOSING;

EID: 84927933558     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2014.10.008     Document Type: Review

References (105)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377(9783):2127-37.
2. Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl. 2). ii1-44.
3. Rudwaleit M, van der Heijde D, Landewe R, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70(1):25-31.
4. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68(6):777-83.
5. Machado P, Landewe R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69(8):1465-70.
6. Ariza-Ariza R, Hernandez-Cruz B, Collantes E, et al. Work disability in patients with ankylosing spondylitis. J Rheumatol 2009;36(11):2512-6.
7. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70(11):1921-5.
8. Healey EL, Haywood KL, Jordan KP, et al. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol 2011;40(1):34-40.
9. Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2014 [in press].
10. Baraliakos X, Listing J, von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitiseevidence for major individual variations in a large proportion of patients. J Rheumatol 2009;36(5):997-1002.
11. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973;1(7809):904-7.
12. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70(8):1369-74.
13. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64(5):1388-98.
14. Ward MM, Hendrey MR, Malley JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 2009;61(7):859-66.
15. Bartolome N, Szczypiorska M, Sanchez A, et al. Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. Rheumatol (Oxford) 2012;51(8):1471-8.
16. WeiW, Lu Q, Chaudry GJ, et al. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 2006;124(6):1141-54.
17. Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol 2013;9(6): 328-39.
18. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107(4):513-23.
19. Minamizaki T, Yoshiko Y, Kozai K, et al. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone 2009;44(6):1177-85.
20. Namikawa T, Terai H, Hoshino M, et al. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine 2007;32(21):2294-9.
21. Toyoda H, Terai H, Sasaoka R, et al. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Bone 2005;37(4):555-62.
22. Lin Z, Bei JX, Shen M, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet 2012;44(1):73-7.
23. Watanabe H, Yamada Y. Chondrodysplasia of gene knockout mice for aggrecan and link protein. Glycoconj J 2002; 19(4-5):269-73.
24. Watanabe H, Yamada Y. Mice lacking link protein develop dwarfism and craniofacial abnormalities. Nat Genet 1999; 21(2):225-9.
25. Urano T, Narusawa K, Shiraki M, et al. Single-nucleotide polymorphism in the hyaluronan and proteoglycan link protein 1 (HAPLN1) gene is associated with spinal osteophyte formation and disc degeneration in Japanese women. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 2011;20(4):572-7.
26. Choi EY, Chavakis E, Czabanka MA, et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 2008;322(5904):1101-4.
27. Eskan MA, Jotwani R, Abe T, et al. The leukocyte integrin antagonist del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol 2012;13(5):465-73.
28. Takai A, Inomata H, Arakawa A, et al. Anterior neural development requires del1, a matrix-associated protein that attenuates canonical Wnt signaling via the Ror2 pathway. Development 2010;137(19):3293-302.
29. Ehlen HW, Chinenkova M, Moser M, et al. Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. J Bone Min Res Off J Am Soc Bone Min Res 2013;28(2):246-59.
30. Haroon N, Maksymowych WP, Rahman P, et al. Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the spondyloarthritis research consortium of Canada cohort. Arthritis Rheum 2012;64(4):1119-26.
31. Maksymowych WP, Suarez-Almazor M, Chou CT, et al. Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis. Ann Rheum Dis 1995;54(4):321-4.
32. Haroon N, Tsui FW, Uchanska-Ziegler B, et al. Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis. Ann Rheum Dis 2012; 71(4):589-95.
33. Cortes A, Maksymowych WP, Wordsworth BP, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis 2014 [in press].
34. Ball J. The enthesopathy of ankylosing spondylitis. Br J Rheumatol 1983;22(4 Suppl. 2):25-8.
35. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971;30(3):213-23.
36. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998;352(9134): 1137-40.
37. McGonagle D, Lories RJ, Tan AL, et al. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007;56(8):2482-91.
38. Baeten D, Breban M, Lories R, et al. Spondyloarthritides: related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013 Jan;65(1):12-20.
39. Lories RJ, Baeten DL. Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(4 Suppl. 55):S10-4.
40. De Bari C, Dell'Accio F, Luyten FP. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 2001;44(1):85-95.
41. De Bari C, Dell'Accio F, Tylzanowski P, et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001;44(8):1928-42.
42. De Bari C, Dell'Accio F, Vanlauwe J, et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum 2006;54(4):1209-21.
43. Marinova-Mutafchieva L, Taylor P, Funa K, et al. Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum 2000;43(9):2046-55.
44. Binks DA, Gravallese EM, Bergin D, et al. Role of vascular channels as a novel mechanism for subchondral bone damage at cruciate ligament entheses in osteoarthritis and inflammatory arthritis. Ann Rheum Dis 2013 [in press].
45. Francois RJ. Some pathological features of ankylosing spondylitis as revealed by microradiography and tetracycline labelling. Clin Rheumatol 1982;1(1):23-9.
46. Francois RJ, Gardner DL, Degrave EJ, et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000;43(9):2011-24.
47. Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006;54(6):1805-13.
48. Appel H, Loddenkemper C, Grozdanovic Z, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006;8(5):R143.
49. Appel H, Maier R, Loddenkemper C, et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol 2010;37(4): 823-8.
50. Lories RJ, Matthys P, de Vlam K, et al. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis 2004;63(5):595-8.
51. Lefebvre V, Bhattaram P. Vertebrate skeletogenesis. Curr Top Dev Biol 2010;90:291-317.
52. Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol 2011;7(12):700-7.
53. Lories RJ, Schett G. Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum Dis Clin N Am 2012;38(3):555-67.
54. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115(6):1571-9.
55. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13(2):156-63.
56. Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010;69(3):592-7.
57. Ruiz-Heiland G, Horn A, Zerr P, et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 2012;71(3):400-7.
58. Park MC, Park YB, Lee SK. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol 2008;37(3):200-4.
59. Grcevic D, Jajic Z, Kovacic N, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010;37(2):246-56.
60. Chen HA, Chen CH, Lin YJ, et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol 2010;37(10):2126-32.
61. Korkosz M, Gasowski J, Leszczynski P, et al. Effect of tumour necrosis factor-alpha inhibitor on serum level of dickkopf- 1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand J Rheumatol 2014;43(1):43-8.
62. Daoussis D, Liossis SN, Solomou EE, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62(1):150-8.
63. Taylan A, Sari I, Akinci B, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012;13:191.
64. Klingberg E, Nurkkala M, Carlsten H, et al. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 2014;41(7):1349-56.
65. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60(11):3257-62.
66. Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(4):572-4.
67. Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 2010;6(2):75-81.
68. Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012;64(6):1713-9.
69. Lories RJ, de Vlam K, Luyten FP. Are current available therapies disease-modifying in spondyloarthritis? Best Pract Res Clin Rheumatol 2010;24(5):625-35.
70. Lories RJ, Dougados M. Inflammation and ankylosis: still an enigmatic relationship in spondyloarthritis. Ann Rheum Dis 2012;71(3):317-8.
71. van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58(10):3063-70.
72. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58(5):1324-31.
73. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11(4):R127.
74. Lories RJ, Derese I, de Bari C, et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56(2):489-97.
75. Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatol (Oxford) 2008;47(5):605-8.
76. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65(10):2645-54.
77. Sieper J, Appel H, Braun J, et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008;58(3):649-56.
78. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009;11(2):221.
79. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat(+) CD3(+) CD4(+)CD8(+) entheseal resident T cells. Nat Med 2012;18(7):1069-76.
80. Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med 2012;18(7):1018-9.
81. Colbert RA, DeLay ML, Klenk EI, et al. From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev 2010;233(1):181-202.
82. DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009;60(9):2633-43.
83. Turner MJ, Delay ML, Bai S, et al. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum 2007;56(1):215-23.
84. Turner MJ, Sowders DP, DeLay ML, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005;175(4):2438-48.
85. Ciccia F, Accardo-Palumbo A, Rizzo A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 2013 Aug;73(8):1566-74. http://dx.doi.org/10.1136/annrheumdis-2012-202925.
86. Neerinckx B, Carter S, Lories RJ. No evidence for a critical role of the unfolded protein response in synovium and blood of patients with ankylosing spondylitis. Ann Rheum Dis 2014;73(3):629-30.
87. Mielants H, Veys EM, Cuvelier C, et al. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985;12(2):294-8.
88. Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72(3):414-7.
89. Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009;649:57-70.
90. Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014;73(2):437-45.
91. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73(8):1455-61.
92. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60(1):93-102.
93. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008;10(5):R104.
94. van der Heijde D, Machado P, Braun J, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(3): 369-73.
95. Chiowchanwisawakit P, Lambert RG, Conner-Spady B, et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011; 63(8):2215-25.
96. Pedersen SJ, Chiowchanwisawakit P, Lambert RG, et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 2011;38(7):1349-54.
97. Maksymowych WP, Morency N, Conner-Spady B, et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013; 72(1):23-8.
98. Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008;14(12):1363-9.
99. Braem K, Deroose CM, Luyten FP, et al. Inhibition of inflammation but not ankylosis by glucocorticoids in mice: further evidence for the entheseal stress hypothesis. Arthritis Res Ther 2012;14(2):R59.
100. Tsui FW, Tsui HW, Las Heras F, et al. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 2013 Oct;73(10):1873-9. http://dx.doi.org/10.1136/annrheumdis-2013- 203630.
101. Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976;5(1):60-4.
102. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52(6):1756-65.
103. Kroon F, Landewe R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012 Oct;71(10):1623-9. http://dx.doi.org/10. 1136/annrheumdis-2012-201370.
104. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Ann Rheum Dis 2013 Aug;72(8):1430-2. http://dx.doi.org/10.1136/annrheumdis-2012-203148.
105. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73(4):710-5.